HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

Structure of 150008-24-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

{[proInfo.proName]}

CAS No.: 150008-24-5

4.5 *For Research Use Only !

{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 150008-24-5 ] Purity: 98% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 150008-24-5 ]

CAS No. :	150008-24-5
Formula :	C₁₀H₁₈N₂O₃
M.W :	214.26
SMILES Code :	O=C(N1CC/C(CC1)=N/O)OC(C)(C)C
MDL No. :	MFCD09953970
InChI Key :	LDLQTMSUZKHEHY-UHFFFAOYSA-N
Pubchem ID :	15462924

Safety of [ 150008-24-5 ]

GHS Pictogram:
Signal Word:	Danger
Hazard Statements:	H228-H302-H317-H319-H341-H351
Precautionary Statements:	P280-P210-P240-P264-P270-P301+P310-P330-P370+P378-P403+P233-P405-P501
Class:	4.1
UN#:	1325
Packing Group:	Ⅱ

Computational Chemistry of [ 150008-24-5 ] Show Less

Physicochemical Properties

Num. heavy atoms	15
Num. arom. heavy atoms	0
Fraction Csp3	0.8
Num. rotatable bonds	3
Num. H-bond acceptors	4.0
Num. H-bond donors	1.0
Molar Refractivity	61.01
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	62.13 ?2

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	2.41
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	0.82
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	1.47
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	0.74
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	0.86
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	1.26

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-1.49
Solubility	6.98 mg/ml ; 0.0326 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-1.71
Solubility	4.21 mg/ml ; 0.0196 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-0.97
Solubility	23.0 mg/ml ; 0.107 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	No
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-7.02 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	0.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	3.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	2.42

Application In Synthesis of [ 150008-24-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 150008-24-5 ]

[ 150008-24-5 ] Synthesis Path-Downstream 1~32

1
2-chloro-1,3-dimethyl imidazolium chloride [ No CAS ]
[ 150008-24-5 ]
[ 190900-21-1 ]

Yield	Reaction Conditions	Operation in experiment
		To a solution of tert-butyl 4-(hydroxyimino)piperidinone carboxylate (32.70 g) in acetonitrile (250 mL), 2-chloro-1,3-dimethylimidazolynium chloride (30.96 g) was added, to which triethylamine (51 mL) was added dropwise at room temperature over 20 minutes. After dropwise addition, it was further stirred at room temperature for 30 minutes, and then water (50 mL) was added and stirred overnight. After the reaction mixture was diluted with ethyl acetate, the organic layer was separated. The organic layer was washed in 0.1 mol/L hydrochloric acid, a saturated aqueous solution of sodium bicarbonate and saturated saline in this order, and then dried on anhydrous magnesium sulfate, and filtered. The solvent was evaporated under reduced pressure, dried under vacuum to obtain a crude title compound as a brown semi-solid compound. The product was used in the subsequent reaction without further purification.

References: [1]Patent: EP1477490,2004,A1 .Location in patent: Page 109.

2
[ 79099-07-3 ]
[ 150008-24-5 ]

Yield	Reaction Conditions	Operation in experiment
100%	With hydroxylamine hydrochloride; sodium acetate; In methanol; water;Reflux;	All of the oxime substrates used in this investigation were synthesized in quantitative yields by refluxing a mixture of 1 equiv of the corresponding ketones or aldehydes, 1.6 equiv of hydroxylamine hydrochloride, and 2.0 equiv of sodium acetate in aqueous methanol.
100%	With hydroxylamine hydrochloride; sodium acetate; In ethanol; water;	To a solution of tert-butyl 4-piperidinone carboxylate in ethanol (400 mL), hydroxylamine hydrochloride (29.34 g) and sodium acetate (34.64 g) were added, and stirred at 100C for seven hours. The reaction mixture was cooled to room temperature, and the filtrate obtained by filtering off the solid was concentrated under reduced pressure. Water was added to the residue, and extracted twice with ethyl acetate. The combined organic layer was washed in a saturated aqueous solution of sodium bicarbonate and saturated saline, and then dried on anhydrous magnesium sulfate, and filtered. The solvent was evaporated under reduced pressure, dried under vacuum to obtain a title compound (quantitative yield) as a white solid compound. 1H-NMR (400 MHz, DMSO-d6) delta(ppm): 1.46 (s, 9H), 2.27 (m, 2H), 2.49 (m, 2H), 3.36-3.52 (m, 4H), 10.50 (s, 1H).
96%		Hydroxylamine hydrochloride (2.50 g, 36.0 mmol) was added to a solution of l-Boc-4-piperidone (6.10 g, 30.0 mmol) and sodium acetate (2.95 g, 36.0 mmol) in ethanol (60 ml) and the whole was stirred at room temperature for 1 hour. The reaction mixture was concentrated in vacuo and the residue was diluted with ethyl acetate (120 ml) and washed with saturated aqueous NaHCO3 (30 ml) and brine, dried over MgSO4 and concentrated in vacuo. The residual solid was recrystallized from ethyl acetate/n-hexane to give tert-butyl 4- (hydroxyimino)piperidine-1-carboxylate (6.18 g, 96 %) as a white solid.

65%	With hydroxylamine hydrochloride; In pyridine; at 65℃; for 1h;	To a solution of N-t-butoxycarbonyl-4-piperidone 1 (15 g, 75.3 mmol) in pyridine (50 mL) was added hydroxylamine ? HCl (5.23 g, 75.3 mmol). The mixture was heated in an oil bath at 65 C for 1 h. After cooling, pyridine was removed under reduced pressure and the residue was dried under high vacuum overnight to give a solid. To this solid was added water (100 mL) and the mixture was sonicated. The precipitate was filtered and washed with water then dried under high vacuum to give the oxime derivative of compound 1 (10.5 g, 65%); FAB MS [M+1]+ 215.3. The oxime (10 g, 46.67 mmol) was dissolved in absolute EtOH (100 mL) followed by the addition of Raney Ni (29 g, washed with absolute EtOH). The mixture was hydrogenated in a Parr shaker at 50 psi overnight. After reaction was complete, the Raney Ni was filtered off (caution; risk of fire) and the filtrate was concentrated to give compound 2 (9.2 g, 46 mmol,98% yield) as an oil which solidified under high vacuum drying. FAB MS [M+1]+ 201.3. To a solution of the bromoacetamide derivative 3 (3.0g,6.2 mmol) (prepared in Example 3) in CH2Cl2 (62 mL) at -10 C were added Huenig's base (1.2 mL, 6.82 mmol) and compound 2 (2.48 g, 12.39 mmol). The solution was gradually warmed to RT overnight. After reaction was complete, CH2Cl2 (300 mL) was added and the mixture was washed with brine (100 mL, 3x), dried over MgSO4 and filtered. The filtrate was evaporated to dryness to give a light yellow solid which was purified by flash chromatography on silica gel (200 g), eluting with 5% [NH4OH/MeOH (1:9)] /CH2Cl2 to give a 71% yield of the title compound 4 as a white solid (2.66 g, 4.4 mmol), m.p. 78-81 C; FAB MS [M+1]+35Cl 603.1; Calcd. for C31H40N4O4Cl2, C, 61.69; H, 6.68; N,9.28; Cl,11.74. Found: C, 61.33; H, 6.94; N, 9.17; Cl, 11.27.
46.4%	With hydroxylamine hydrochloride; sodium acetate; In ethanol; at 90℃; for 12h;	To a stirred solution of tert-butyl 4-oxopiperidine-1 -carboxylate (10.00 g, 0.0502 mol) in ethanol (100 mL) hydroxylamine hydrochloride (6.98 g, 0.100 mol) and CH3COONa (8.23 g, 0.100 mol) were added, then heated to 90 C for 12 h under nitrogen atmosphere. After completion of the reaction by LCMS, the reaction mixture was concentrated and to the crude material water (100 mL) was added followed by extraction by using dichloromethane (250 mL).The organic layer was concentrated and the crude product was purified by silica gel column (Biotage) using 18- 30% of ethyl acetate in pet ether to obtain tert-butyl-4-(hydroxyimino)piperidine-1-carboxylate (5 g, 46.4 %) as a white solid. (0830) MS: 159.1 (M+H)+- t-butyl (0831) 1H-NMR (400 MHz, DMSO- 6) d = 10.45 (s, 1 H), 3.33-3.36 (m, 4H), 2.42-2.44 (m, 2H), 2.20- 2.22 (m, 2H), 1.41 (s, 9H).
	With hydroxylamine hydrochloride; In pyridine; at 20℃;Molecular sieve;	To a solution of /ert-butyl 4-oxopiperidine-l-carboxylate (50 g, 251 mmol) in pyridine (500 mL) is added molecular sieves (50 g) and the mixture is stirred at room temperature for 10 minutes, followed by the addition of NH2OH HCl (30.25 g, 427 mmol). The resulting reaction is stirred at room temperature overnight, and the reaction mixture filtered through a pad of celite to remove the molecular sieves. The filtrate is diluted with water, the layers separated and the aqueous phase extracted with more ethyl acetate. The combined organic phases are washed with brine, dried over EPO <DP n="25"/>MgSO4, filtered, and concentrated in vacuo to provide the title compound. This material is used in the next step without further purification.1H NMR (300 MHz, DMSO-ddelta): 1.52 (s, 9H), 2.36 (t, J=6.0 Hz, 2H), 2.58 (t, J=6.0 Hz, 2H), 3.50-3.58 (m, 4H).
	With hydroxylamine hydrochloride; sodium acetate; In ethanol; at 100℃; for 7h;	To a solution of I-48 (50 g, 0.25 mol, 1.0 eq) in ethanol (300 mL) hydroxylamine hydrochloride (35 g, 0.50 mol, 2.0 eq) was added followed by sodium acetate (41 g, 0.50 mol, 2.0 eq) and the reaction mixture was stirred at 100 C. for 7 hours. Solids were removed by filtration and the filtrate was concentrated by evaporation. Water was added to the residue; the reaction mixture was extracted with ethyl acetate and washed with aqueous sodium bicarbonate and brine. The combined organic layers were dried on anhydrous MgSO4, the solids were removed by filtration and the filtrate was concentrated to give intermediate I-49 (54 g, 100%) as white solid that was used in the following step without further purification. MS (ESI): m/z 159.1 (M+H+).
	With hydroxylamine hydrochloride; sodium acetate; In ethanol; water; at 15℃; for 2h;	To a solution of tert-butyl 4-oxopiperidine-1-carboxylate (20.0 g, 100 mmol) and sodium acetate (9.88 g, 120 mmol) in a mixture of ethanol (160 mL) and water (40 mL) was added hydroxylamine hydrochloride (8.37 g, 120 mmol) and the reaction mixture was stirred at 15 C for 2 hrs. On completion, the reaction mixture was concentrated in vacuo, and 300 mL water and 300 mL dichloromethane was added. The aqueous phase was extracted with dichloromethane (3 × 100 mL). The combined layer was dried over anhydrous sodium sulfate and concentrated in vacuo to give the title compound. 1H NMR (300MHz, CDCl3) delta = 8.71 (br. s., 1H), 3.55 (q, J = 6.8 Hz, 4H), 2.63 (t, J = 6.0 Hz, 2H), 2.35 (t, J = 6.0 Hz, 2H), 1.49 (s, 9H).
	With hydroxylamine hydrochloride; triethylamine; In ethanol; at 0 - 20℃; for 6h;Heating / reflux;	Example 2 Synthesis of Compound 191 EPO <DP n="18"/>A solution of 5.8 g (0.31 mol) of N-t-Boc-piperidone in 80 ml of ethanol was cooled to O0C on an ice bath. To this was added 5.2 ml (0.04 mol) of TEA then 2.6 g (0.37 mol) of solid hydroxylamine HCl. The mixture was warmed to room temperature and then heated to reflux temperature for 6 h. The solvent was removed and the solid was partitioned between saturated aqueous ammonium chloride and ethyl acetate (100 ml each). The aqueous layer was extracted with a second portion of ethyl acetate (100 ml) and the combined extract was dried over sodium sulfate. The solvent was removed at reduced pressure to afford 6.0 g of a white solid. The solid was dissolved in 60 ml of methanol and then hydrogenated over 5% Rhodium on Alumina (0.6 g) at 5O0C. After the uptake of hydrogen ceased, the catalyst was filtered and the solvent removed to afford 5.5 g (98%) of reactant 5. The NMR spectrum was consistent with the proposed structure.

References: [1]Bioorganic and Medicinal Chemistry Letters,2010,vol. 20,p. 2942 - 2945.
[2]Tetrahedron Letters,2010,vol. 51,p. 3216 - 3217.
[3]Tetrahedron Letters,2011,vol. 52,p. 1074 - 1077.
[4]Patent: EP1477490,2004,A1 .Location in patent: Page 109.
[5]Patent: WO2008/150447,2008,A1 .Location in patent: Page/Page column 206.
[6]Bioorganic and Medicinal Chemistry Letters,2011,vol. 21,p. 983 - 988.
[7]Patent: EP937069,2006,B1 .Location in patent: Page/Page column 46-47.
[8]Patent: WO2019/134978,2019,A1 .Location in patent: Page/Page column 124.
[9]Patent: WO2006/56877,2006,A2 .Location in patent: Page/Page column 23-24.
[10]Tetrahedron Letters,2009,vol. 50,p. 148 - 151.
[11]Patent: US2010/204214,2010,A1 .Location in patent: Page/Page column 108.
[12]Patent: WO2017/156177,2017,A1 .Location in patent: Paragraph 00318.
[13]Patent: WO2006/105056,2006,A2 .Location in patent: Page/Page column 16-17.

3
[ 150008-24-5 ]
[ 190900-21-1 ]

Yield	Reaction Conditions	Operation in experiment
84%	With 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane-2,4,6-trioxide; In tetrahydrofuran; ethyl acetate; at 70℃;Inert atmosphere;	To a solution of ketoxime (0.01 mol) in THF (10 mL) was added T3P (15 mol percent, 50percent soln in EtOAc) and the resulting reaction mixture was stirred at reflux for 1-4 h under nitrogen atmosphere. When the reaction was completed as confirmed by TLC, the solvent was removed under vacuum and the residue was diluted with water (20 mL). The product was extracted with ethyl acetate (2 .x. 20 mL) and the combined organic phase was washed with saturated NaHCO3 solution (1 .x. 10 mL) and brine. The organic phase was dried over anhydrous Na2SO4. The solvent was removed under reduced pressure to afford the desired amides in good purity.
48%		To a solution of intermediate I-49 (11 g, 50 mmol, 1.0 eq) in acetone (60 mL) was added a solution of Na2CO3 (16 g, 150 mmol, 3.0 eq) in water (80 mL) and the reaction mixture was stirred for 5 minutes. A solution of p-toluenesulfonyl chloride (14 g, 75 mmol, 1.5 eq) in acetone (20 mL) was added slowly and the reaction mixture was stirred at room temperature for 3 hours. Excess solvent was removed by evaporation, water was added and the reaction mixture was extracted with dichloromethane. The combined organic layers were dried over anhydrous MgSO4, the solids were removed by filtration and the filtrate was concentrated by evaporation. The crude reaction product was purified by silica gel column chromatography to give intermediate I-50 (5.0 g, 48percent). MS (ESI): m/z 159.1 (M+H+).
		To a solution of tert-butyl 4-(hydroxyimino)piperidine-l-carboxylate (1 O g, 4.67 mmol) in acetone (20 mL) is added a solution OfNa2CO3 (1.48 g, 14 mmol) in water (20 mL), and the mixture is stirred for 5 minutes, then a solution of p- toluenesulfonyl chloride (1.33 g, 7 mmol) in acetone (5 mL) is added slowly. The reaction is stirred at room temperature for 3h, then the acetone is removed in vacuo, water is added, and the solution extracted with dichloromethane. The organic layer is dried over MgSO4, filtered, concentrated in vacuo, and purified by chromatography (6percent MeOH in dichloromethane) to afford the title compound.1H NMR (300 MHz, DMSO-ds): 1.41 (s, 9H), 2.40 (m, 2H), 3.09 (m, 2H), 3.39-3.44 (m, 4H), 7.62 (m, IH).

References: [1]Tetrahedron Letters,2011,vol. 52,p. 1074 - 1077.
[2]Patent: US2010/204214,2010,A1 .Location in patent: Page/Page column 108.
[3]Patent: WO2006/56877,2006,A2 .Location in patent: Page/Page column 24.
[4]Tetrahedron Letters,2009,vol. 50,p. 148 - 151.

4
[ 150008-24-5 ]
[ 87120-72-7 ]

Yield	Reaction Conditions	Operation in experiment
98%	With hydrogen;Raney nickel; In ethanol; under 2585.81 Torr;	To a solution of N-t-butoxycarbonyl-4-piperidone 1 (15 g, 75.3 mmol) in pyridine (50 mL) was added hydroxylamine ? HCl (5.23 g, 75.3 mmol). The mixture was heated in an oil bath at 65 C for 1 h. After cooling, pyridine was removed under reduced pressure and the residue was dried under high vacuum overnight to give a solid. To this solid was added water (100 mL) and the mixture was sonicated. The precipitate was filtered and washed with water then dried under high vacuum to give the oxime derivative of compound 1 (10.5 g, 65%); FAB MS [M+1]+ 215.3. The oxime (10 g, 46.67 mmol) was dissolved in absolute EtOH (100 mL) followed by the addition of Raney Ni (29 g, washed with absolute EtOH). The mixture was hydrogenated in a Parr shaker at 50 psi overnight. After reaction was complete, the Raney Ni was filtered off (caution; risk of fire) and the filtrate was concentrated to give compound 2 (9.2 g, 46 mmol,98% yield) as an oil which solidified under high vacuum drying. FAB MS [M+1]+ 201.3. To a solution of the bromoacetamide derivative 3 (3.0g,6.2 mmol) (prepared in Example 3) in CH2Cl2 (62 mL) at -10 C were added Huenig's base (1.2 mL, 6.82 mmol) and compound 2 (2.48 g, 12.39 mmol). The solution was gradually warmed to RT overnight. After reaction was complete, CH2Cl2 (300 mL) was added and the mixture was washed with brine (100 mL, 3x), dried over MgSO4 and filtered. The filtrate was evaporated to dryness to give a light yellow solid which was purified by flash chromatography on silica gel (200 g), eluting with 5% [NH4OH/MeOH (1:9)] /CH2Cl2 to give a 71% yield of the title compound 4 as a white solid (2.66 g, 4.4 mmol), m.p. 78-81 C; FAB MS [M+1]+35Cl 603.1; Calcd. for C31H40N4O4Cl2, C, 61.69; H, 6.68; N,9.28; Cl,11.74. Found: C, 61.33; H, 6.94; N, 9.17; Cl, 11.27.
	With hydrogen;5% rhodium on activated aluminium oxide; In methanol; at 50℃;	Example 2 Synthesis of Compound 191 EPO <DP n="18"/>A solution of 5.8 g (0.31 mol) of N-t-Boc-piperidone in 80 ml of ethanol was cooled to O0C on an ice bath. To this was added 5.2 ml (0.04 mol) of TEA then 2.6 g (0.37 mol) of solid hydroxylamine HCl. The mixture was warmed to room temperature and then heated to reflux temperature for 6 h. The solvent was removed and the solid was partitioned between saturated aqueous ammonium chloride and ethyl acetate (100 ml each). The aqueous layer was extracted with a second portion of ethyl acetate (100 ml) and the combined extract was dried over sodium sulfate. The solvent was removed at reduced pressure to afford 6.0 g of a white solid. The solid was dissolved in 60 ml of methanol and then hydrogenated over 5% Rhodium on Alumina (0.6 g) at 5O0C. After the uptake of hydrogen ceased, the catalyst was filtered and the solvent removed to afford 5.5 g (98%) of reactant 5. The NMR spectrum was consistent with the proposed structure.

References: [1]Patent: EP937069,2006,B1 .Location in patent: Page/Page column 46-47.
[2]Bioorganic and Medicinal Chemistry Letters,2011,vol. 21,p. 983 - 988.
[3]Patent: WO2006/105056,2006,A2 .Location in patent: Page/Page column 16-17.

5
[ 79099-07-3 ]
[ 497-19-8 ]
[ 150008-24-5 ]

Yield	Reaction Conditions	Operation in experiment
1.86 g (87%)	With hydroxylamine hydrochloride; In methanol;	a N-tert-Butoxycarbonyl-4-piperidone oxime To a stirred suspension of hydroxylamine hydrochloride (0.84 g, 12.0 mmol) in methanol (10 mL) at 0 C. was added solid Na2 CO3 (0.64 g, 6.0 mmol). The mixture was stirred for ca. 5 min. N-t-Boc-4-piperidone (1.99 g, 10.0 mmol) was added and the mixture was stirred for ca 2 h. The reaction mixture was concentrated in vacuo to ca. half its original volume, then diluted with saturated NaHCO3 (100 mL) and extracted with CHCl3 (4*50 mL). The combined organic layers were dried over Na2 SO4, filtered, and concentrated in vacuo to yield 1.86 g (87%) of the desired product as a tan solid. MS (ES+) m/z 215.0 [M+H]+.

References: [1]Patent: US6077857,2000,A .

6
[ 79099-07-3 ]
4-hydroxyiminopiperidine trifluoroacetate [ No CAS ]
[ 150008-24-5 ]

Yield	Reaction Conditions	Operation in experiment
	With triethylamine; In methanol; chloroform; hydroxylamine hydrochloride;	REFERENCE EXAMPLE 1 4-hydroxyiminopiperidine trifluoroacetate The above identified compound can be prepared in accordance with the following formulas. STR13 15.5 g (77.6 mmol) of N-Boc-4-piperidone was refluxed for one hour in methanol in the presence of 7.0 g (100.8 mmol) of hydroxylamine hydrochloride and 14.1 ml (100.8 mmol) of triethylamine. Then, methanol was distilled off, and the residue was thoroughly washed with water in chloroform. The chloroform layer was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure to give 10.6 g of N-Boc-4-hydroxyiminopiperidine as white powder. Melting point: 92-93 C. MS(M/Z): 114(M+ --Boc), 97(--OH), 85, 69, 56 1 H-NMR delta(CDCl3): 1.48(9H,s), 2.32-2.37(2H,m), 2.60-2.64(2H,m), 3.50-3.57(4H,m).

References: [1]Patent: US5276041,1994,A .

7
[ 150008-24-5 ]
[ 1195-45-5 ]
[ 1092464-56-6 ]

Yield	Reaction Conditions	Operation in experiment
96%	With triethylamine; In tetrahydrofuran; at 0℃; for 4.16667h;	A solution of 4-fluorophenylisocyanate (775 mg, 5.65 mmol) in tetrahydrofuran (20 ml) was added to a solution of tert-butyl 4-(hydroxyimino)piperidine-1- carboxylate (1.00 g, 4.67 mmol) and triethylamine (0.783 ml, 5.65 mmol) in tetrahydrofuran (30 ml) at 0C over 10 minutes and stirred at 0C for 4 hours. The mixture was concentrated in vacuo and the residual solid was recrystallized from ethyl acetate/n-hexane to give tert- butyl 4-(4-fluorophenylcarbamoyloxyimino)piperidine-1-carboxylate (1.57 g, 96 %) as a white solid.

References: [1]Patent: WO2008/150447,2008,A1 .Location in patent: Page/Page column 206.

8
[ 150008-24-5 ]
[ 372-48-5 ]
[ 1095264-39-3 ]

Yield	Reaction Conditions	Operation in experiment
23%		tert-Butyl 4-oxo-3-(2-oxo-1,2-dihydropyridin-3-yl)piperidine-1-carboxylate Potassium tert-butoxide (1.22 g, 10.8 mmol) were added to <strong>[150008-24-5]tert-butyl 4-(hydroxyimino)piperidine-1-carboxylate</strong> (2.11 g, 9.85 mmol) in DMF (10 mL) at 0 C. under argon. The resulting suspension was stirred for 20 mins. 2-Fluoropyridine (0.85 mL, 9.85 mmol) was added to the reaction mixture and the resulting solution was stirred at 80 C. for 21 hours. The reaction mixture was poured into ice water (100 mL) and extracted with EtOAc (250 mL). The organic layers were combined and washed with brine (250 mL). The organic layer was dried over Na2SO4, filtered and evaporated to afford crude product. Flash column chromatography (silica, gradient 5 to 100% EtOAc in isohexane) yielded tert-butyl 4-oxo-3-(2-oxo-1,2-dihydropyridin-3-yl)piperidine-1-carboxylate (0.654 g, 23%) as a cream solid. MS (+ve ESI): 293 (M+H)+ 1H NMR (400.13 MHz, CDCl3) delta 1.50 (9H, s), 2.64 (2H, s), 3.41 (1H, s), 3.48 (2H, t), 3.73 (1H, s), 4.26 (2H, s), 6.26 (1H, t), 7.24-7.27 (1H, m), 7.30-7.32 (1H, m)
		To a suspension of sodium hydride (0.268 g, 7.00 mmol) in DMF (3 ml_) the title compound from Step A above (0.500 g, 2.33 mmol) was added drop wise (dissolved in DMF 5 mL) at 0 (0833) C, then stirred at room temperature for 60 min. After that 2-fluoropyridine (0.340 g, 3.50 mmol) was added dropwise at 0 C (dissolved in DMF 2 mL) and then stirred at room temperature for 3 h. After completion of the reaction by TLC, the reaction mixture was quenched with ice water followed by extraction using ethyl acetate (30 mL). The organic layer was separated, dried over sodium sulphate, filtered and then concentrated to obtain tert-butyl 4-oxo-3-(2-oxo-1 ,2-dihydropyridin-3-yl)piperidine-1-carboxylate (300 mg, crude) as a pale brown solid. The crude product was taken as such for next step. (0834) MS: 293.2 (M+H)+.

References: [1]Patent: US2009/12077,2009,A1 .Location in patent: Page/Page column 31.
[2]Patent: WO2019/134978,2019,A1 .Location in patent: Page/Page column 124; 125.

9
[ 446-48-0 ]
[ 150008-24-5 ]
[ 1229313-22-7 ]